Mundipharma Completes Enrollment for Pivotal ReSPECT Trial Evaluating Rezafungin in Preventing Fungal Infections
Table of Contents
A new global study offers hope for improved antifungal prophylaxis in vulnerable patients undergoing bone marrow transplants.
Mundipharma announced today the completion of patient enrollment for the Phase III ReSPECT trial, a landmark study evaluating Rezzayo® (rezafungin) for the prevention of invasive fungal disease in adult patients undergoing allogeneic blood and marrow transplantation. Topline results from the trial are anticipated by mid-2026.
Addressing a Critical Unmet Need
The ReSPECT trial is a randomized, double-blind, controlled, pivotal Phase 3 study designed to compare rezafungin to standard antimicrobial regimens. The goal is to prevent invasive fungal diseases caused by Candida, Aspergillus, and Pneumocystis – infections that pose a significant threat to individuals with weakened immune systems following bone marrow transplants.
“Completing patient enrollment for the Phase III ReSPECT study marks a key milestone in addressing the unmet need for antifungal prevention in immunosuppressed patients,” stated a senior official at Mundipharma. “Patients have enrolled in this global study from more than 50 clinical trial centers across seven countries. We look forward to the clinical evidence that this study will produce.”
The Threat of Invasive Candidiasis
Invasive candidiasis (IC) remains a serious concern, particularly for critically ill and immunocompromised patients. Despite existing treatments, the mortality rate associated with IC can be as high as 40%. This severe, life-threatening infection manifests as a systemic Candida infection affecting the bloodstream and/or deep tissues.
Rezafungin is already approved for the treatment of invasive candidiasis in adults, and the ReSPECT trial aims to determine its efficacy in preventing these infections from occurring in the first place.
Mundipharma’s Global Reach and Commitment
Mundipharma is a global healthcare company operating across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East. The company’s mission, “United for Patients,” underscores its dedication to developing and delivering innovative treatments across a range of therapeutic areas, including infectious disease. Commercialization rights for rezafungin in the United States have been licensed to CorMedix Inc.
The ReSPECT trial represents a significant step forward in the ongoing effort to protect vulnerable patients from the devastating consequences of invasive fungal infections. The results, expected in mid-2026, will be closely watched by the medical community and could potentially reshape the standard of care for antifungal prophylaxis in bone marrow transplant recipients.
